MedTrace Logo

Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis

NCT04312594 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2024-12-12

No results posted yet for this study

Summary

This is a multi-center, randomized, double-blinded, and placebo-controlled phase II study to evaluate the efficacy and safety of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis.

Conditions

Interventions

DRUG

Jaktinib Hydrochloride Tablets

Patients were administered Jaktinib taken orally as tablets twice daily

DRUG

Jaktinib Hydrochloride Tablets

Patients were administered Jaktinib taken orally as tablets twice daily

DRUG

Placebo

Patients were administered Placebo taken orally as tablets twice daily

Sponsors & Collaborators

  • Suzhou Zelgen Biopharmaceuticals Co.,Ltd

    lead INDUSTRY

Principal Investigators

  • Jason Wu · Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-08
Primary Completion
2022-06-09
Completion
2022-06-09

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04312594 on ClinicalTrials.gov